Crescent Biopharma, Inc.

Crescent Biopharma, Inc. is a clinical-stage biotechnology company dedicated to developing oncology therapeutics for solid tumors. The company's vision is to become a world-leading oncology firm, aiming to deliver the next generation of transformative therapies for cancer patients. Established in 2024 through a reverse merger with GlycoMimetics, Inc., Crescent Biopharma maintains its principal offices in Waltham, Massachusetts, USA, and is incorporated in the Cayman Islands.

The company's pipeline is centered on antibody-based drug candidates, with its lead program being CR-001, a PD-1 x VEGF bispecific antibody currently undergoing a Phase 1/2 global clinical trial (ASCEND study) for various solid tumor types. Additionally, Crescent Biopharma is advancing antibody-drug conjugate (ADC) programs, including CR-002 (a PD-L1-targeted ADC) and CR-003 (an ITGB6-targeted ADC), which are designed to deliver targeted cytotoxic payloads. The company has also formed a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of CR-001 and CR-003.

Crescent Biopharma is publicly traded on the NASDAQ under the ticker symbol CBIO. Joshua T. Brumm was appointed Chief Executive Officer in March 2025, leading a team focused on advancing the company's clinical programs. The company anticipates submitting an Investigational New Drug (IND) application for CR-001 in the fourth quarter of 2025, with initial clinical data expected in the second half of 2026. As a clinical-stage entity, its public disclosures primarily focus on research and development activities, clinical trials, financing, and capital structure.